Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCastration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease
Urologic Oncology: Seminars and Original Investigations, 07/01/09
Mostaghel EA et al. - In a review of androgen metabolic pathways in recurrent castration-resistant prostate cancer (PC), targeting these metabolic enzymes either individually or using combinations of agents to inhibit testicular, adrenal, and intracrine sources may provide enhanced clinical responses in both localized and metastatic disease.
Methods- Evidence suggests that despite testicular androgen ablation, residual androgens, likely of adrenal—though potentially of prostatic—origin, play a critical role in progression of PC to recurrent castration-resistant disease.
- Reassessment of the concept of total androgen deprivation is warranted.
- Current treatment strategies may not only lack optimal efficacy, but may actually contribute to selection of neoplastic clones adapted to exist and proliferate in a low (but not zero) androgen environment.
- Adequacy of androgen receptor (AR) pathway inhibition cannot be surmised from serum or plasma androgen levels, but must be ascertained at the tissue and molecular level prior to drawing conclusions regarding clinical efficacy or failure.
- Recent studies indicate that PCs undergo an adaptive response to castration that is associated with the up-regulation of transcripts encoding enzymes involved in the biosynthesis of androgens.
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/14/09
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09
Sponsor
Article Search
Sponsor
Sponsor